Review source snapshots checked September 15, 2026 · Integrity checked September 15, 2026.
Three selected reports cover early retatrutide studies and the later TRANSCEND-T2D-1 phase 3 diabetes trial. Populations, comparators and primary endpoints differ across the studies.↗↗↗
What the reviewed sources report
Selected trials reported weight reduction and improved glycated hemoglobin. The newer phase 3 diabetes study supports a glycemic effect in its studied population, but these reports do not establish prevention of long-term complications; gastrointestinal adverse events and discontinuations matter.↗↗↗
What remains unresolved?
Do Phase 3 trials confirm durability, rare harms, and clinically important outcomes across more diverse populations?↗↗
How do participant flow, missing outcomes, protocol history and linked corrections affect interpretation of the selected reports?↗↗↗
Investigational status remains separate from trial progress
FDA’s September 1, 2026 page states that retatrutide is not a component of an FDA-approved drug and cannot be used in compounding under federal law. FDA source ↗
More findings and the sources behind them
A dated FDA statement and two sponsor-submitted ClinicalTrials.gov records; registry status and planned endpoints are distinct from reported trial outcomes.
TRIUMPH-1 is marked completed
The August 21 registry record for NCT05929066 reports 2,335 actual participants and April 30, 2026 completion. Its registered outcomes include weight change, sleep-apnea and knee-osteoarthritis subsets. The retrieved record has no posted summary results; completion alone is not an efficacy finding. NCT05929066 ↗
Cardiovascular and kidney outcomes are still being studied
NCT06383390 is active, not recruiting, in its August 24 record. It lists cardiovascular and kidney composite endpoints, estimated enrollment of 10,000, and estimated completion in February 2029. No summary results are posted in the retrieved record. NCT06383390 ↗
What remains to be checked
Match new obesity outcome publications and sponsor reports to their protocols before incorporating results; absence of registry results does not mean no results exist elsewhere.
Complete full-text appraisal of the existing selected literature review and follow long-term outcome trials.
Source dates and review coverage
PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.
Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.
Catalog-name and calibrated alias discovery for human evidence review. Complete query retrieval is separate from clinical eligibility, study-family linkage and appraisal.
183 retrieved · 3 included · 0 excluded · 180 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
"Retatrutide"[Title/Abstract] OR "LY3437943"[Title/Abstract]
Retrieved IDs completely represent this query response, not all relevant literature. Additional aliases, references and non-PubMed sources require separate searches.
Unscreened records may include animal or cell experiments, reviews, secondary analyses, mixtures, protocols and unrelated name matches.
Study-family mappings use available declared registry IDs; unresolved mappings do not create independent trial counts. Full-text, corrections and registry comparison remain separate work.
The selected newer trials are not a completed screen of this entire title/abstract search. Additional primary, secondary, safety and protocol reports remain to be appraised.
Showing 25 of 183 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
PubMed 42250575 — include: Selected primary trial report; the abstract and record metadata were read. Inclusion is not completed full-text appraisal. Study families: NCT06354660.
PubMed 37385280 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT04867785.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
PubMed 37366315 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT04881760.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
PubMed 42734711 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42722378 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42721492 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42690722 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42688617 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42683980 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42682157 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42673585 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42669023 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42649514 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42630988 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42624955 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42608321 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42603384 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42602523 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42590128 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42568490 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42567543 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42562129 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42559975 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42556625 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42536830 — not screened: Name-query match awaiting clinical eligibility screening.
FDA search
Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.
1 retrieved · 0 included · 0 excluded · 1 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 1 of 1 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA 70585 — not screened: Title-name match awaiting identity and document review. P/0336/2024 : EMA decision of 13 September 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for retatrutide (EMEA-003258-PIP02-23)
EMA search
Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov search
ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.
35 retrieved · 0 included · 0 excluded · 35 awaiting a decision · 0 full-text appraisals
Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
Other registries, unregistered studies and additional aliases remain outside this query.
Showing 25 of 35 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov NCT04881760 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06354660 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05916560 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06297603 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05931367 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06260722 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06383390 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05548231 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07165028 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06313528 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06039826 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05882045 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04143802 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06003465 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04823208 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05959096 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06859268 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05929066 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05929079 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07226947 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06808802 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07035093 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05445232 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT03841630 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06982859 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
Read the full Human Evidence Review
Supervised synthesis
What do selected human studies report about Retatrutide?
Three selected reports cover early retatrutide studies and the later TRANSCEND-T2D-1 phase 3 diabetes trial. Populations, comparators and primary endpoints differ across the studies.123
Bottom line from this bounded source set
Selected trials reported weight reduction and improved glycated hemoglobin. The newer phase 3 diabetes study supports a glycemic effect in its studied population, but these reports do not establish prevention of long-term complications; gastrointestinal adverse events and discontinuations matter.123
Reviewed study record
Phase 2 obesity trial
Design
A double-blind, randomized, placebo-controlled Phase 2 trial followed participants for 48 weeks and assessed body-weight change and safety.1
Population
The trial enrolled 338 adults with obesity, or overweight plus at least one weight-related condition.1
Outcomes reported
At 48 weeks, reported mean body-weight change ranged from -8.7% to -24.2% across retatrutide groups, compared with -2.1% for placebo. Gastrointestinal events were the most common adverse events, and heart-rate increases peaked at 24 weeks before declining.1
Limitations
This was a sponsor-funded Phase 2 trial with 48-week follow-up; it was not a long-term cardiovascular-outcomes or rare-harms study.1
Reviewed study record
Phase 2 type 2 diabetes trial
Design
A randomized, double-blind, placebo- and active-comparator-controlled Phase 2 trial evaluated glycated hemoglobin at 24 weeks and body weight at 36 weeks.2
Population
The trial randomized 281 adults with type 2 diabetes and elevated body-mass index at 42 U.S. centers; 275 were included in efficacy analyses.2
Outcomes reported
At 24 weeks, reported glycated-hemoglobin changes ranged from -0.43 to -2.02 percentage points across retatrutide groups, compared with -0.01 for placebo and -1.41 for the active comparator. Reported body-weight change at 36 weeks ranged from -3.19% to -16.94% across retatrutide groups.2
Limitations
The sponsor-funded trial had 36-week follow-up, 79% completed treatment, and 84% of participants were White; those features limit conclusions about durability and generalizability.2
Reviewed study record
TRANSCEND-T2D-1: phase 3 diabetes study
Design
A blinded randomized placebo-controlled trial assessed 40-week glycated hemoglobin change under NCT06354660.3
Population
The trial randomized 537 adults with type 2 diabetes inadequately controlled with diet and exercise alone.3
Outcomes reported
Under the treatment-regimen analysis, HbA1c decreased by 1.69–1.94 percentage points across active groups versus 0.81 with placebo. Gastrointestinal events were common; adverse-event discontinuations occurred in 2–5% of active groups and none of the placebo group.3
Limitations
HbA1c and weight changes do not establish prevention of long-term complications. The report recorded two deaths in one active group, which the authors considered unrelated to study treatment; it reported no severe hypoglycemia.3
No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1056/nejmoa2301972. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1016/s0140-6736(23)01053-x. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1016/s0140-6736(26)00967-0. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
Explore status sources, recent additions, and coverage gaps
Living status brief
What is the current status of Retatrutide?
Investigational. ClinicalTrials.gov lists an Eli Lilly study as active, not recruiting, with a registry update posted July 20, 2026.↗
The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.
PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
Bibliography fields unavailable here for 10 selected records; the records remain visible as metadata observations.
Regulatory and publication surfaces
What is structurally connected?
Drugs@FDA applications
0
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
21
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
PeptideScanner retained ClinicalTrials.gov record NCT05929066 at 2026-09-09T19:17:17.407Z. Its registry update date was 2026-08-21, and PeptideScanner's reviewed identity mapping was retatrutide.
PeptideScanner retained ClinicalTrials.gov record NCT06383390 at 2026-09-09T19:17:17.103Z. Its registry update date was 2026-08-24, and PeptideScanner's reviewed identity mapping was retatrutide.
PeptideScanner retained ClinicalTrials.gov record NCT05882045 at 2026-08-10T18:10:03.944Z. Its registry update date was 2026-07-30, and PeptideScanner's reviewed identity mapping was retatrutide.
Counts and links describe PeptideScanner’s selected records. They are not rankings and do not establish research quality, safety, effectiveness, or medical relevance.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
These dates come from selected source records and PubMed metadata. They are not a complete or continuous timeline of research, safety, approval, or effectiveness.
Evidence summary
What the cited records say
ClinicalTrials.gov lists an Eli Lilly study as active, not recruiting, with a registry update posted July 20, 2026.↗
This is a source summary, not a medical recommendation. Status may differ by jurisdiction and product.
PeptideScanner retained ClinicalTrials.gov record NCT06383390 at 2026-09-09T19:17:17.103Z. Its registry update date was 2026-08-24, and PeptideScanner's reviewed identity mapping was retatrutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT05929066 at 2026-09-09T19:17:17.407Z. Its registry update date was 2026-08-21, and PeptideScanner's reviewed identity mapping was retatrutide.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42567543 at 2026-08-10T10:49:13.603Z. PubMed recorded a metadata revision date of 2026-08-07 and an Entrez history date of 2026-08-07. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 38323122 at 2026-08-10T10:49:06.879Z. PubMed recorded a metadata revision date of 2026-07-31 and an Entrez history date of 2024-02-07. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained ClinicalTrials.gov record NCT05882045 at 2026-08-10T18:10:03.944Z. Its registry update date was 2026-07-30, and PeptideScanner's reviewed identity mapping was retatrutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT05929079 at 2026-08-10T18:10:04.224Z. Its registry update date was 2026-07-30, and PeptideScanner's reviewed identity mapping was retatrutide.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42527705 at 2026-08-10T18:13:57.053Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-07-29. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42493254 at 2026-08-10T18:13:56.730Z. PubMed recorded a metadata revision date of 2026-07-23 and an Entrez history date of 2026-07-23. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42425580 at 2026-08-10T18:13:55.212Z. PubMed recorded a metadata revision date of 2026-07-09 and an Entrez history date of 2026-07-09. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42264536 at 2026-07-30T16:14:18.135Z. PubMed recorded a metadata revision date of 2026-06-09 and an Entrez history date of 2026-06-09. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41056349 at 2026-07-30T16:20:41.592Z. PubMed recorded a metadata revision date of 2026-05-22 and an Entrez history date of 2025-10-07. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.↗